10<sup>th</sup> Annual Hematologic Malignancies Demystified
Meeting Series
Meeting Series

10th Annual Hematologic Malignancies Demystified

The Series (2018 Edition) A Critical Appraisal of Data From 2017

Not a member of My prIME? Join now for instant access.

Meeting Overview

Explore the options in hematology and hematologic malignancies with this live meeting. Stay informed on new data with established agents and gain insight into the use of novel agents in your practice. Expert faculty will focus on updates from recent congresses and the latest clinically relevant data.

CME

CME

5.75 AMA PRA Category 1 Credits

CE

CE

5.75 Contact Hours

This meeting series has ended.

Chicago, Illinois

Westin Chicago River North
320 North Dearborn Street
Chicago, Illinois 60654
312.744.1900

Saturday, January 13, 2018

7.00 AM  Registration & continental breakfast
8.00 AM  Program overview
8.10 AM  Acute leukemia
Richard M. Stone, MD
8.40 AM  Myelodysplastic syndromes
Guillermo Garcia-Manero, MD
9.10 AM  Myeloproliferative neoplasms
Ruben Mesa, MD, FACP
9.40 AM  Oncology Guru™ hematology quiz
9.50 AM  Break
10.20 AM  Chronic myelogenous leukemia
Jorge Cortes, MD
10.50 AM  Hodgkin lymphoma
Barbara Pro, MD
11.20 AM  Non-Hodgkin lymphoma
Julie Vose, MD, MBA
11.50 AM  Chronic lymphocytic leukemia
Susan O’Brien, MD
12.20 PM  Oncology Guru™ hematology quiz
12.30 PM  Lunch
1.30 PM  Multiple myeloma
Sagar Lonial, MD
2.10 PM  What’s new in transplant
Sergio Giralt, MD, FACP
2.40 PM  Benign hematology
Stephan Moll, MD
3.00 PM  Oncology Guru™ hematology quiz
3.10 PM  Discussion and concluding remarks

Back to Top

New York, New York

Intercontinental Times Square
300 West 44th Street
New York, New York 10036
212.803.4500

Saturday, January 20, 2018

7.00 AM  Registration & continental breakfast
8.00 AM  Program overview
8.10 AM  Acute leukemia
Richard M. Stone, MD
8.40 AM  Myelodysplastic syndromes
Guillermo Garcia-Manero, MD
9.10 AM  Myeloproliferative neoplasms
Srdan Verstovsek, MD, PhD
9.40 AM  Oncology Guru™ hematology quiz
9.50 AM  Break
10.20 AM  Chronic myelogenous leukemia
Jorge Cortes, MD
10.50 AM  Hodgkin lymphoma
Barbara Pro, MD
11.20 AM  Non-Hodgkin lymphoma
Julie Vose, MD, MBA
11.50 AM  Chronic lymphocytic leukemia
Susan O’Brien, MD
12.20 PM  Oncology Guru™ hematology quiz
12.30 PM  Lunch
1.30 PM  Multiple myeloma
Kenneth Anderson, MD
2.10 PM  What’s new in transplant
Sergio Giralt, MD, FACP
2.40 PM  Benign hematology
Stephan Moll, MD
3.00 PM  Oncology Guru™ hematology quiz
3.10 PM  Discussion and concluding remarks

Back to Top

Atlanta, Georgia

Intercontinental Buckhead Atlanta
3315 Peachtree Road, NE
Atlanta, Georgia 30326
404.946.9000

Saturday, January 27, 2018

7.00 AM  Registration & continental breakfast
8.00 AM  Program overview
8.10 AM  Acute leukemia
Richard M. Stone, MD
8.40 AM  Myelodysplastic syndromes
Guillermo Garcia-Manero, MD
9.10 AM  Myeloproliferative neoplasms
Srdan Verstovsek, MD, PhD
9.40 AM  Oncology Guru™ hematology quiz
9.50 AM  Break
10.20 AM  Chronic myelogenous leukemia
Jorge Cortes, MD
10.50 AM  Hodgkin lymphoma
Barbara Pro, MD
11.20 AM  Non-Hodgkin lymphoma
Julie Vose, MD, MBA
11.50 AM  Chronic lymphocytic leukemia
Anthony Mato, MD
12.20 PM  Oncology Guru™ hematology quiz
12.30 PM  Lunch
1.30 PM  Multiple myeloma
Sagar Lonial, MD
2.10 PM  What’s new in transplant
Corey Cutler, MD, MPH
2.40 PM  Benign hematology
Stephan Moll, MD
3.00 PM  Oncology Guru™ hematology quiz
3.10 PM  Discussion and concluding remarks

Back to Top

Houston, Texas

Hyatt Regency Houston/Galleria
2626 Sage Road
Houston, Texas 77056
832.803.1234

Saturday, February 3, 2018

7.00 AM  Registration & continental breakfast
8.00 AM  Program overview
8.10 AM   Benign hematology
Stephan Moll, MD
8.40 AM  Myelodysplastic syndromes
Guillermo Garcia-Manero, MD
9.10 AM  Myeloproliferative neoplasms
Srdan Verstovsek, MD, PhD
9.40 AM  Oncology Guru™ hematology quiz
9.50 AM  Break
10.20 AM  Chronic myelogenous leukemia
Jorge Cortes, MD
10.50 AM  Hodgkin lymphoma
Craig Moskowitz, MD
11.20 AM  Non-Hodgkin lymphoma
Ajay Gopal, MD
11.50 AM  Chronic lymphocytic leukemia
Susan O’Brien, MD
12.20 PM  Oncology Guru™ hematology quiz
12.30 PM  Lunch
1.30 PM  Multiple myeloma
Kenneth Anderson, MD
2.10 PM  What’s new in transplant
Partow Kebriaei, MD
2.40 PM  Acute leukemia
Richard M. Stone, MD
3.00 PM  Oncology Guru™ hematology quiz
3.10 PM  Discussion and concluding remarks

Back to Top

    Course Director

  • Hagop Kantarjian, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Local Chair – Chicago

  • Parameswaran Venugopal, MDRush University
    Chicago, Illinois, United States
  • Local Chair – New York

  • Karen Seiter, MDNew York Medical College
    Valhalla, New York, United States
  • Local Chair – Atlanta

  • Martha Arellano, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia
  • Faculty

  • Kenneth Anderson, MDHarvard Medical School and Dana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Corey Cutler, MD, MPH, FACP(C)Dana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Guillermo Garcia-Manero, MDThe University of Texas, MD Anderson Cancer Center
    Houston, Texas, United States
  • Sergio Giralt, MD, FACPMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Ajay Gopal, MDUniversity of Washington and
    Fred Hutchinson Cancer Research Center
    Seattle, Washington, United States
  • Partow Kebriaei, MDUniversity of Texas
    MD Anderson Cancer Center
    Houston, Texas
  • Sagar Lonial, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Anthony Mato, MD Memorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Ruben Mesa, MD, FACPUT Health San Antonio Cancer Center
    San Antonio, Texas, United States
  • Stephan Moll, MDUniversity of North Carolina, School of Medicine
    Chapel Hill, North Carolina, United States
  • Craig Moskowitz, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Susan O'Brien, MDUC Irvine Health
    Chao Family Comprehensive Cancer Center
    Orange, California, United States
  • Barbara Pro, MDRobert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois, United States
  • Richard M. Stone, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Srdan Verstovsek, MD, PhDThe University of Texas, MD Anderson Cancer Center
    Houston, Texas, United States
  • Julie Vose, MD, MBAUniversity of Nebraska Medical Center
    Omaha, Nebraska, United States

Fee for Activity
Physician, pharmacist, other healthcare professionals: $150
Nurse/Nurse practitioner/Physician assistant: $40
Nonclinical attendee and pharmaceutical industry representative: $800

Physicians receive a 50% discount if registering prior to January 1, 2018.

Fellows/Residents/Students
Use ID code FRS for complimentary registration. Credit card information will still be required for registration. A $25 “no-show” fee will be charged if you register, but fail to attend the meeting, and have not canceled your registration. Cancellations will be accepted without incurring a fee, up to 72 hours prior to the meeting.

ONS Members
ONS members are eligible for discounted rates. Please email hemehighlights@prIMEoncology.org with the name of your ONS chapter for more information.

The registration fee includes all activity materials, breakfast, lunch, and refreshment breaks. prIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.

Cancellations/Substitutions Policy
The registration fee is nonrefundable. Substitutions will be accepted up to one week prior to the meeting date with written notice.

This educational activity is specifically designed for practicing medical oncologists, hematologists, registered nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in and/or involved in the treatment of patients with cancer in the United States.

After successful completion of this educational activity, participants should be able to:

Physicians

  • Assess new and emerging data with established treatment options
  • Evaluate safety and efficacy data from recent and ongoing clinical trials
  • Distinguish the adverse event profiles of different options for hematologic malignancies
  • Evaluate expert recommendations for monitoring treatment response and managing adverse events

Nurses

  • Evaluate safety and efficacy data from recent and ongoing clinical trials
  • Identify the most common treatment-associated side effects in hematologic treatment agents and select appropriate strategies for prevention, recognition, and management of these events
  • Evaluate the clinical evidence for, and counsel patients on the importance of, the utilization of cytogenetic markers, minimal residual disease, and other prognostic/predictive tests

This educational activity is supported by grants from AbbVie Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Celgene Corporation; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Novartis Oncology; Seattle Genetics, Inc.; and Takeda Oncology.

Additional support opportunities are available for this activity series. For information on educational grant support or exhibit information, please contact:
Lisa Willey, Accounts Services Coordinator
Lisa.Willey@prIMEoncology.org
Office: +1 678.686.7751

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

10th Annual Hematologic Malignancies Demystified - prIME Oncology

prIME Oncology designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.  This educational activity for 5.75 contact hours is provided by Postgraduate Institute for Medicine.

A statement of credit will be issued only upon receipt of a completed activity evaluation form. You will receive an email to claim your certificate shortly after the meeting.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA Disclosure

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.